Tags : Dr. Reddy

Insights+: COVID-19 Healthcare News Monthly Updates – August 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

Insights+: COVID-19 Healthcare News Monthly Updates – July 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

Insights+: The US FDA New Drug Approvals in May 2020

The US FDA has approved multiple NDAs and BLAs in May 2020, leading to the treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 43 novel products so far in 2020, including 12 in May 2020. […]Read More

Dr. Reddy’s Elyxyb (celecoxib oral solution) Receives the US FDA’s

Shots: ELYXYB (previously as DFN-15) is an oral solution formulated using a self-micro emulsifying drug delivery system helps in improving solubility and bioavailability of the drug leading for absorption The candidate demonstrated a rapid onset of actions important for suffering from acute migraine and resulted in efficacy with few AEs NSAIDs including ELYXYB can lead […]Read More

Insights+ Key Biosimilars Events of September 2019

Biosimilars are key alternatives for costly Biologics therapies and saving millions of dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of the […]Read More

Dr. Reddy Plans the Onset of P-III trial for DRL_RI

Shots: The P-III trial involves assessing of DRL_RI vs Roche’s MabThera (rituximab) in 284 patients including 26 Koreans, with stage II-IV, CD20 positive, and follicular lymphoma previously treated have low tumor burden, evaluating its efficacy, safety, and immunogenicity Dr. Reddy’s plan to evaluate DRL_RI in Korea while Paraxel to provide clinical research services and Korea’s […]Read More

Encore Dermatology to Acquire US Commercialization Rights for Dr. Reddy’s

Shots: Encore through its subsidiary Promius Pharma, has acquired US commercialization rights for Sernivo spray (betamethasone dipropionate), Trianex (Triamcinolone Acetonide Ointment, USP) and Promiseb from Dr. Reddy The focus of the acquisition is to expand Encore’s portfolio of dermatology products for the treatment of skin diseases such as psoriasis, atopic dermatitis and acne Sernivo (betamethasone […]Read More

Dr. Reddy’s Tosymra (sumatriptan nasal spray) 10mg Receives the US

Shots: The approval is based on the clinical trial assessing Tosymra in patients with a migraine and demonstrated well tolerated and safe results Promius Pharma’s (subsidiary of Dr. Reddy) Tosymra (previously known as DFN-02) is a nasal spray developed using Intravail platform, targeted to treat adults with migraine with or without aura, to achieve equivalent […]Read More

Dr. Reddy Launched Hervycta (biosimilar Trastuzumab) in India

Shots: Hervycta (biosimilar Trastuzumab) indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer and metastatic gastric cancer)  Marketed as 150mg and 440mg multiple dose vials  As per Dr. Reddy, it has four biosimilars commercialized in India Click here to read full press release/ article | Ref: Dr. Reddy Laboratories | Image: Dr […]Read More